You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 24, 2024

DEPO-SUBQ PROVERA 104 Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Depo-subq Provera 104, and what generic alternatives are available?

Depo-subq Provera 104 is a drug marketed by Pfizer and is included in one NDA.

The generic ingredient in DEPO-SUBQ PROVERA 104 is medroxyprogesterone acetate. There are twenty drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the medroxyprogesterone acetate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Depo-subq Provera 104

A generic version of DEPO-SUBQ PROVERA 104 was approved as medroxyprogesterone acetate by BARR on August 9th, 1996.

  Sign Up

AI Research Assistant
Sample questions
  • What is the 5 year forecast for DEPO-SUBQ PROVERA 104?
  • What are the global sales for DEPO-SUBQ PROVERA 104?
  • What is Average Wholesale Price for DEPO-SUBQ PROVERA 104?
Drug patent expirations by year for DEPO-SUBQ PROVERA 104
Recent Clinical Trials for DEPO-SUBQ PROVERA 104

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Oregon Health and Science UniversityEarly Phase 1
University of British ColumbiaPhase 4
Canadian Institutes of Health Research (CIHR)Phase 4

See all DEPO-SUBQ PROVERA 104 clinical trials

Pharmacology for DEPO-SUBQ PROVERA 104
Drug ClassProgestin

US Patents and Regulatory Information for DEPO-SUBQ PROVERA 104

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer DEPO-SUBQ PROVERA 104 medroxyprogesterone acetate INJECTABLE;SUBCUTANEOUS 021583-001 Dec 17, 2004 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for DEPO-SUBQ PROVERA 104

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0113964 97C0037 Belgium ⤷  Sign Up PRODUCT NAME: OESTROGENES EQUINS CONJUGUES; ACETATE DE MEDROXYPROGESTERONE; NAT. REGISTRATION NO/DATE: NL 19569 19950301; FIRST REGISTRATION: CH - 52647 01 010 19940826
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.